Vera Therapeutics
VERA
160 hedge funds and large institutions have $2.21B invested in Vera Therapeutics in 2024 Q1 according to their latest regulatory filings, with 73 funds opening new positions, 52 increasing their positions, 31 reducing their positions, and 8 closing their positions.
813% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 8
247% more capital invested
Capital invested by funds: $637M → $2.21B (+$1.58B)
68% more funds holding
Funds holding: 95 → 160 (+65)
68% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 31
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
4.48% more ownership
Funds ownership: 93.25% → 97.73% (+4.5%)
62% less call options, than puts
Call options by funds: $6.1M | Put options by funds: $16M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$188M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$85.3M |
| 3 |
Holocene Advisors
New York
|
+$43M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$29.8M |
| 5 |
SC
Samlyn Capital
New York
|
+$23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$81.4M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$75.7M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$55.6M |
| 4 |
O
OrbiMed
New York
|
-$30M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
-$27.1M |
VERA Hedge Fund Activity: Q1 2024 in Review
160 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Vera Therapeutics (VERA) for Q1 2024, worth a combined $2.21B — up 247% from $637M a quarter earlier.
Buyers outnumbered sellers: 73 funds opened new VERA positions and 8 closed out — a net gain of 65 holders — while 52 added to existing stakes and 31 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $188M. The largest seller was Commodore Capital, cutting an estimated $81.4M.
- 160 institutional investors held Vera Therapeutics (VERA) as of Q1 2024, up from 95 in Q4 2023.
- Funds reported $2.21B of Vera Therapeutics stock for Q1 2024, up 247% quarter-over-quarter.
- 73 funds opened new Vera Therapeutics positions in Q1 2024 and 8 closed out, a net change of +65 holders.
- The largest Vera Therapeutics buyer in Q1 2024 was Avoro Capital Advisors, an estimated $188M added.
- The largest Vera Therapeutics seller in Q1 2024 was Commodore Capital, an estimated $81.4M sold.
Based on aggregated 13F filings for Q1 2024.